DeuteRx is involved in improving medicines for patients. This description is self-described.

DeuteRx

Celgene Corporation is a biopharmaceutical company specializing in the development and commercialization of cancer and immunology drugs. Its major product is Revlimid (lenalidomide), used in the treatment of multiple myeloma and certain anemias.

Sol Barer

Robert J. Hariri

Celgene Corporation

Poxel SA is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, focusing on non-alcoholic steatohepatitis (NASH) and rare disorders.

Poxel SA

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). The company has a licensing agreement with Enyo Pharma S.A.S. for the development of PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist that is in Phase II study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

Poxel S.A.

DeuteRx | 254 followers on LinkedIn. Devoted to improving patients&#39; lives and advancing small molecule therapies through Deuterium-Enriched Chiral Switching. | Formed in 2012, DeuteRx is a virtual biopharmaceutical company focused on improving racemic drugs for patients. Our team has pioneered the use of Deuterium-Enabled Chiral Switching (DECS) to isolate a single stereoisomer from a mixture of interconverting stereoisomers. 

DECS is a revolutionary strategy that stabilizes the preferred stereoisomer in existing drugs sold as racemic mixtures to reduce deleterious side-effects and improve efficacy.

Life Sciences Executive & Serial Entrepreneur

Sheila DeWitt, PhD

Life Sciences CEO | Specializing in Early-stage Companies

Mike Webb

Founder, President, Chairman & CSO at RIFFIT

Lex Van Der Ploeg

Check out the results of our collaborative research effort with POXEL ! #PXL065 is the deuterium-stabilized (R)-enantiomer of pioglitazone and may be a safer and more effective NASH treatment than racemic pioglitazone. #NASH #NonAlcoholicSteatohepatitis #drugdiscovery #drugdevelopment #liverhealth #liverdisease #pioglitazone #DECS #DeuteriumEnabledChiralSwitching #DeuteRx #deuterium #racemic #enantiomer #innovationinhealthcare

Metric
Company Name	DeuteRx	Celgene Corporation	Poxel SA	Poxel S.A.
Symbol				POXEL
MSH ID	COM:DEUTERX	COM:CELGENE	COM:POXEL	COM:POXELPHARMA
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services	Healthcare
Industry	Pharmaceuticals	Biotechnology	Biotechnology	Biotechnology
Country	US		FR	FR
Stage			Post-IPO Debt	Post-IPO Debt
Employee Count		10.00K		15
Website	deuterx.com	celgene.com	poxel.com	poxelpharma.com
LinkedIn	deuterx		poxel	poxel
Founders

Metric
Market Cap		24.02M
Enterprise Value
Monthly Web Traffic	4.88K	4.88K
Web Traffic Growth	-0.63	-0.63
Valuation
Raised Capital	50M	50M

Metric
Revenue				2.09M
Revenue (LTM)
Revenue (NTM)
Gross Profit				2.09M
EBITDA				2.09M
Operating Income				2.09M
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				-8.02
Operating Profit Margin				0.34
EBITDA Margin				1
Net Profit Margin				-13.25
Return on Equity				1.68
Return on Assets
Return on Capital Employed

DEUT

COM:DEUTERX

DeuteRx

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				-0.46
P/B Ratio				-0.79
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				17.73
EV Multiple				2.13

Metric
Days Sales Outstanding
Days Payables Outstanding				1.60K
Days Inventory Outstanding				57.08
Operating Cycle				345.25
Cash Conversion Cycle				321.84
Asset Turnover				0.41

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales				-4.65
Free Cash Flow Yield				-1.13

Metric
Cash & Equivalents				2.47M
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets				1.25
Current Ratio				0.60
Quick Ratio				0.12

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue				4.18
R&D to Revenue				20.68
SG&A to Revenue				6.59